Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
GSK’s first lung cancer approval, a new IPO path and more
This week on “The Top Line,” Fierce Healthcare and Life Sciences’ editor-in-chief steps behind the microphone for a solo episode highlighting several of the biggest stories in biopharma. | This week on “The Top Line”: GSK’s lung cancer approval, an unusual IPO strategy and a push to update animal testing rules.
TL;DRAI
GSK secures first lung cancer approval (Jideytro) via Nuvalent; Axiom pursues Hong Kong IPO before Nasdaq in resurgent biotech market. Pharma M&A and cross-border IPO patterns signal capital markets reshaping in health innovation—important for CTO evaluating biotech partnerships and governance.
289 words~1 min read
